LEXICON PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
LXRX$1.82+2.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In thousands, except per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenues: | |||
| Net product revenue | $1,110 | $— | $— |
| Royalties and other revenue | 94 | 139 | 298 |
| Total revenues | 1,204 | 139 | 298 |
| Operating expenses: | |||
| Cost of sales | 85 | — | — |
| Research and development, including stock-based compensation of $5,139, $4,253 and $4,284 respectively | 58,887 | 52,816 | 55,046 |
| Selling, general and administrative, including stock-based compensation of $9,201, $7,267 and $6,293, respectively | 113,982 | 48,083 | 32,342 |
| Total operating expenses | 172,954 | 100,899 | 87,388 |
| Loss from operations | (171,750) | (100,760) | (87,090) |
| Interest and other expense | (13,101) | (2,780) | (802) |
| Interest income and other, net | 7,732 | 1,596 | 134 |
| Net loss | $(177,119) | $(101,944) | $(87,758) |
| Net loss per common share, basic and diluted | $(0.80) | $(0.62) | $(0.60) |
| Shares used in computing net loss per common share, basic and diluted | 221,130 | 165,733 | 145,652 |
| Other comprehensive loss: | |||
| Unrealized gain (loss) on investments | 459 | (418) | (4) |
| Comprehensive loss | $(176,660) | $(102,362) | $(87,762) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.